A phase II trial of regorafenib for advanced urothelial cancer (aUC) following prior chemotherapy von Naik, Gurudatta, Vaishampayan, Ulka N., Nabell, Lisle, De Shazo, Mollie R., Nandagopal, Lakshminarayanan, Grivas, Petros, Morgan, Charity, Hardwick, Pamela, Sonpavde, Guru

Volltext

Effect of obesity on response to checkpoint inhibitors in renal cell cancer von Nandagopal, Lakshminarayanan, Zakharia, Yousef, Yasin, Hesham, Nepple, Kenneth Gerard, De Shazo, Mollie R., Yang, Eddy Shih-Hsin, Garje, Rohan, Basu, Arnab, Li, Peng, Norian, Lyse

Volltext

Change in neutrophil to lymphocyte ratio (NLR) as a predictor of treatment failure in renal cell carcinoma patients: Analysis of the IROC (Investigating RCC Outcomes) cohort von Basu, Arnab, Phone, Audrey, Bice, Tristan, Sweeney, Patrick, Acharya, Luna, Suri, Yash, Chan, Abigail Sy, Nandagopal, Lakshminarayanan, Garje, Rohan, Zakharia, Yousef, Kilari, Deepak, Koshkin, Vadim S, De Shazo, Mollie R., Barata, Pedro C., Desai, Arpita

Volltext

Phase II trial of carfilzomib for metastatic castration-resistant prostate cancer (mCRPC) following androgen pathway inhibitors von Naik, Gurudatta, Bae, Sejong, De Shazo, Mollie R., Dixon, Pam, Merritt, Lynn, Sartor, A. Oliver, Schnell, Frederick M., Sonpavde, Guru

Volltext